[The potassium salt form of citrate with alkalinizing property. Following absorption, potassium citrate causes increased plasma bicarbonate concentration, thereby raising blood and urinary pH. A simultaneous decrease in calcium ion activity occurs as a result of increasing calcium complex formation with dissociated anions. Levels of urinary citrate are increased due to modification of the renal handling of citrate. By promoting excretion of free bicarbonate ion and by increasing urinary pH in addition to an increased ionization of uric acid to more soluble urate ions, this agent exerts the alkalizing and anti-urolithic effect. ( NCI )]
UMLS (NCI) C0137996 - Organic Chemical
- Pharmacologic Substance
Relation/PAR: [TN410] CITRATES
[TN403] POTASSIUM
CITRATE
Relation/CHD: ISOSOURCE LIQUID (CLOSED SYSTEM)
COMPLEAT MODIFIED LIQUID
COMPLEAT MODIFIED LIQUID (CLOSED SYSTEM)
CRITICARE HN LIQUID
FIBERSOURCE HN LIQUID
FIBERSOURCE LIQUID
ISOSOURCE HN LIQUID (CLOSED SYSTEM)
LONALAC POWDER,ORAL
PSYLLIUM HYDROCOLLOID 3GM PWDR,ORAL
RESOURCE CRYSTALS (CHOCOLATE)
RESOURCE CRYSTALS (VANILLA)
RESOURCE INSTANT CRYSTALS (RICH CHOCOLATE)
RESOURCE LIQUID (CHOCOLATE)
RESOURCE LIQUID (STRAWBERRY)
RESOURCE LIQUID (VANILLA)
RESOURCE PLUS LIQUID (CHOCOLATE)
RESOURCE PLUS LIQUID (VANILLA)
ULTRACAL TUBE-FEEDING LIQUID
EVAC-Q-MAG 300ML/EVAC-Q-SERT SUPP #2/EVAC-Q-TAB 130MG #2 KIT
IMPACT LIQUID
ISOSOURCE HN LIQUID (VANILLA)
RESOURCE PLUS LIQUID (STRAWBERRY)
RESOURCE INSTANT CRYSTALS (VANILLA)
POTASSIUM CITRATE 50 MG
POTASSIUM CITRATE 1100 MG/5ML
potassium citrate 0.333 MEQ/ML
POTASSIUM CITRATE 15 MEQ
POTASSIUM CITRATE 260 MG
POTASSIUM CITRATE 540 MG
POTASSIUM CITRATE 1080 MG
POTASSIUM CITRATE 3300 MG
POTASSIUM CITRATE 216 MG/5ML
potassium citrate 0.94 MEQ/ML
POTASSIUM CITRATE 150 MG
POTASSIUM CITRATE 2 MEQ
POTASSIUM CITRATE 3.3 GM
POTASSIUM CITRATE 430 MG/240ML
POTASSIUM CITRATE 550 MG/5ML
POTASSIUM CITRATE 25 MEQ MG